Related Experiment Video
Updated: Jan 11, 2026
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical
Yingcheng Wang1, Mingjun Rui1, Qiran Wei1
1School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Background:
Maternal vaccination against respiratory syncytial virus (RSV) showed high vaccine efficacy in preventing severe RSV-associated events in newborns in randomized controlled trials. This cost-effectiveness study evaluated year-round and seasonal maternal RSV vaccination in Hong Kong.
Research Design And Methods:
A decision-analytical model was constructed to evaluate the outcomes of three options: Year-round, seasonal, and no vaccination. Direct and indirect costs, RSV-associated lower respiratory infection, hospitalizations, pediatric intensive care unit admissions, deaths, QALYs loss, and incremental cost per QALY saved (ICER) were measured.
Results:
In base-case analysis, both year-round and seasonal vaccination reduced RSV-related events and saved QALYs at higher costs versus no vaccination. ICERs (versus no vaccination) of year-round (585,340 USD/QALY) and seasonal (560,460 USD/QALY) strategies exceeded willingness-to-pay (WTP) threshold 54,101 USD/QALY. Maternal vaccination strategies became cost-effective if RSV vaccine cost < USD67 for seasonal strategy and
Conclusions:
Year-round and seasonal maternal RSV vaccination strategies saved QALYs at a higher cost from a societal perspective in Hong Kong. The cost-effectiveness acceptance of both strategies is highly dependent on the RSV vaccine cost.
